Beruflich Dokumente
Kultur Dokumente
I: Much should be done II: Much could be done III: Much can be and is being done
From anecdote
to evidence
Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries
GTF.CCC
Members
Applies a diagonal approach to avoid the false dilemmas between disease silos -CD/NCD- that continue to plague global health
C) Can be done
Myth 4: Impossible
19%
20%
0%
LMICs
High income
-31%
Facets
Men Women
% of population
40
Both sexes
20
Lower Upper High Low middle middle income Age-standardized prevalence of risk factor in adults aged 15+ years
Children
Leukaemia
All cancers LOW INCOME HIGH INCOME LOW INCOME HIGH INCOME
In Canada, almost 90% of children with leukemia survive. In the poorest countries only 10%.
Cancer especially in Stigma: women and children - adds a layer of discrimination onto ethnicity, poverty, and gender.
C) Can be done
Myth 4: Impossible
Women and mothers in LMICs face many risks through the life cycle Women 15-59, annual deaths
- 35% in 30 years
Mortality in childbirth Breast cancer Cervical cancer Diabetes
342,900
166,577
142,744
120,889
A Diagonal Strategy:
Delivery: Harness platforms by integrating breast and cervical cancer prevention, screening and survivorship care into MCH, SRH, HIV/AIDS, social welfare and anti-poverty programs.
C) Can be done
Myth 4: Impossible
Almost 80% of the DALYs lost worldwide to cancer are in LMICs, yet these countries have only a very small share of global resources for cancer ~ 5% or less.
1/3-1/2 of cancer deaths are avoidable: 2.4-3.7 million deaths - 80% in LIMCs
The costs to close the cancer divide may be less than many fear:
All but 3 of 29 LMIC priority cancer chemo and hormonal agents are off-patent: many < $100 / course Cost of drug treatment: cervical cancer + HL + ALL(kids) in LMICs / year of incident cases: $US 280 m
Pain medication is cheap Prices drop: HPV 2011 from $US 100 /dose to:
GAVI $5 and PAHO $14
Market potential is underutilized and undeveloped Purchasing is fragmented and procurement is unstable Delivery innovations are unexploited
Outcomes in MDR-TB patients in Lima, Peru receiving at least four months of therapy
Failed therapy Abandon 8%
therapy 2%
Died 8%
Cured 83%
Ofloxacin
98%
Champions
Drew G. Faust
President of Harvard University 22+ year BC survivor
Embryonal Rhabdomyosarcoma
0
1965 1975 1985
1955
1995
2008
Source: Knaul et al., 2008. Reproductive Health Matters, and updated by Knaul, Arreola-Ornelas and Mndez based on WHO data, WHOSIS (1955-1978), and Ministry of Health in Mexico (1979-2006)
Mexico, Colombia, Dominican Republic, Peru China, India, Taiwan Rwanda, Kenya
~100%
# of covered services
275
262 266
89%
249
~17.2 millones de familias
9%
1.5
5.1 millones
9.1 millones
146 113
2004
2005
2006
2007
2008
2009
2010
2012
2004
2005
2006
2007
2008
2009
2010
2011
2011
2012
2006: All pediatric cancers then all children and newborns for almost everything
2007: Breast cancer 2011: Testicular cancer, prostate and NHL
Rich
Juanita:
Advanced metastatic breast cancer is the result of a series of missed opportunities
Be an optimist optimalist
Expanding access to cancer care and control in LMICs: Should, Could, and Can be done
@amazon